Investegate |CVC Credit Partners Announcements | CVC Credit Partners: Annual Financial Report investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Janus Henderson s Foll: Why we are overweight banks for first time in years
Performance buoyed by dividend suspensions
Laura Foll of Janus Henderson Investors
All three of Laura Foll and James Henderson s UK equity investment trusts – Law Debenture, Henderson Opportunities Trust and Lowland – moved to an overweight in incumbent banks for the first time in as long as Foll can remember last year, despite the fact all five firms suspended their dividends in 2020.
Foll, who began co-managing mandates alongside Henderson in 2014, told
Investment Week banks are now in a very different position to what they were during the Global Financial Crisis (GFC) of 2008, and that their forced suspension of dividend payouts meant they were trading on particularly attractive valuations relative to history.
| UPDATED: 22:52, Tue, Mar 16, 2021
Link copied Make the most of your money by signing up to our newsletter for FREE now
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Interest rates have undoubtedly been hard hit by the Bank of England’s base rate decision, with the rate remaining at 0.1 percent since March 2020. With a knock on effect for many familiar providers, it has been challenging for individuals who are determined to save. But the situation has not only been dire for easy access accounts, with ISAs also feeling the pinch.
Foreign holdings of sterling deposits have surged to levels not seen since before the 2008 financial crisis, leaving the pound at risk of a steep fall if sentiment should change, a leading economist
socaltech.com
Encinitas-based
Ventyx Biosciences, a developer of immune modulators to treat inflammatory diseases and autoimmune disorders, said this morning that it has raised $114M in an equity funding round. The funding was led by venBio Partners, and also included Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surve
The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please
login in order to access this members-only content, or